The 7 most recent market catalysts affecting $BDRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 65
Biodexa Pharmaceuticals Provides R&D Update on Lead Programs eRapa and MTX240
Biodexa Pharmaceuticals announced significant progress in its eRapa and MTX240 clinical programs. For eRapa, the company expects topline data for its FAP trial around the end of 20…
Oct 24, 2026
Corporate Catalyst
Neutral
Impact 60
Biodexa Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Biodexa Pharmaceuticals is executing a 1-for-8 reverse stock split, a corporate action often undertaken by companies whose stock price has fallen significantly, potentially below e…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 85
Biodexa Pharmaceuticals shares are trading higher after the company announced it enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis.
This headline represents a significant positive corporate catalyst for Biodexa Pharmaceuticals. Reaching 100 patient enrollments in a registrational Phase 3 trial is a crucial de-r…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 65
Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly
Biodexa Pharmaceuticals announced a significant milestone in its registrational Phase 3 Serenta trial for eRapa, having enrolled 100 patients. This trial is crucial for the potenti…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 75
Biodexa Announces ADS Ratio Change To One ADS Per 400 Ordinary Shares, Expected Effective October 26
This ADS ratio change, effectively a reverse stock split, is a significant corporate action for Biodexa. While it doesn't change the underlying value of the company, it's typically…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Biodexa Pharmaceuticals shares are trading higher after the company announced a $2.3 million warrant exercise transaction.
This warrant exercise is a significant corporate catalyst for Biodexa Pharmaceuticals. The $2.3 million infusion provides immediate working capital, which can be used for R&D, clin…
Sep 15, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This filing is a snapshot of pre-market trading activity for a selection of healthcare stocks, indicating significant individual price movements. For Biodexa Pharmaceuticals, the g…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.